Waldenstrom Macroglobulinemia (WM)
Introduction of Waldenstrom Macroglobulinemia (WM) Waldenstrom Macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL), in which the cancer cells make large amounts of an abnormal protein (called a macroglobulin). Another name for this subtype of NHL cancers is lymphoplasmacytic lymphoma. This condition is a rare indolent B-cell lymphoma that occurs in less than two percent of […]
Graft-versus-Host Disease (GvHD)
Quick Review over Graft-versus-Host Disease (GvHD) Introduction: Graft-versus-Host Disease (GvHD) is a common complication because of a transplantation using donor; this complication occurs when the donor’s immune system (the graft) recognizes the patient’s organs and tissues (the host) as unfamiliar cells that should be destroyed. This complication is triggered by a type of white blood cell […]
Cancer Statistics
Cancer statistics According to the American Cancer Society’s annual estimate of 2021, there will be 1898160 new cases and 608570 deaths caused by that in the United States. In generally, due to improvements in various facets of humans’ lives, including availability of different instruments for diagnosing mortality rate has shrunk from its peak in 1991 […]
Protein Tyrosine Kinases:Their Roles and Their Targeting in Leukemia
Protein tyrosine kinases superfamily definition A large group of enzymes that speeding up protein phosphorylation and controlling multiple signaling incidents are titled as Protein tyrosine kinases, which represents a complicated system and is wrapped up by of 518 members. Based on their ability to phosphorylate either tyrosine or serine and threonine residues, they are classified into two main […]
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present) One of the most common and deadliest disease on record is lung cancer. According to estimates with increasing incidence each year, about 85% of lung cancer cases are non-small cell lung cancer type, and about […]
Parsian Pharama Review of CDK4/6 Inhibitors Citing to the Recent Articles
Parsian pharama review of CDK4-6 inhibitors citing to the recent articles One of the most common cancers among women is Breast cancer. Sometimes the average risk of developing breast cancer in a woman in the United States in her lifespan is about 13%. More than 70% of breast cancer cases are Hormone receptor–positive (HR+) types, […]
Aromatase Inhibitors
Parsian pharma review of aromatase inhibitors (AIs) citing to the recent articles regard this subject: Key points that led Parsian pharma to choose Letrozole over other aromatase inhibitors Cell growth in breast cancer is essentially derived by estrogen in both premenopausal and postmenopausal women. Most of the breast cancer cases are among postmenopausal women, […]